$8.72
9.00% yesterday
NYSE, Dec 05, 10:00 pm CET
ISIN
US92332V1070
Symbol
VTYX

Ventyx Biosciences Stock price

$8.72
-0.28 3.11% 1M
+6.47 287.56% 6M
+6.53 298.17% YTD
+6.21 247.41% 1Y
-19.37 68.96% 3Y
-12.30 58.52% 5Y
-12.30 58.52% 10Y
-12.30 58.52% 20Y
NYSE, Closing price Fri, Dec 05 2025
+0.72 9.00%
ISIN
US92332V1070
Symbol
VTYX
Industry

Key metrics

Basic
Market capitalization
$618.7m
Enterprise Value
$426.0m
Net debt
positive
Cash
$192.6m
Shares outstanding
71.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
91.9%
Return on Equity
-53.2%
ROCE
-58.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-117.3m | $-116.0m
EBIT
$-116.7m | $-130.0m
Net Income
$-106.6m | $-121.1m
Free Cash Flow
$-87.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
29.1% | 21.7%
EBIT
29.8% | 12.4%
Net Income
30.1% | 10.4%
Free Cash Flow
45.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-1.2
Short interest
9.2%
Employees
81
Rev per Employee
$0.0
Show more

Is Ventyx Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Ventyx Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Ventyx Biosciences forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Ventyx Biosciences forecast:

Buy
87%
Hold
13%

Financial data from Ventyx Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
10% 10%
-
- Research and Development Expense 88 88
35% 35%
-
-117 -117
29% 29%
-
- Depreciation and Amortization -0.55 -0.55
150% 150%
-
EBIT (Operating Income) EBIT -117 -117
30% 30%
-
Net Profit -107 -107
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Ventyx Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ventyx Biosciences Stock News

Neutral
GlobeNewsWire
4 days ago
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development plan Interim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx's ...
Neutral
GlobeNewsWire
5 days ago
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th ...
Neutral
GlobeNewsWire
19 days ago
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global He...
More Ventyx Biosciences News

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Raju Mohan
Employees 81
Founded 2018
Website ventyxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today